Petros pharmaceuticals executes successful initial test for app comprehension as part of fda pathway for over-the-counter access for stendra(r) (avanafil)

Company is currently conducting larger scale comprehension test to confirm results in compliance with fda discussions new york, ny / accesswire / september 11, 2024 / petros pharmaceuticals, inc. (nasdaq:ptpi) ("petros" or the "company"), a company focused on expanding consumer access to medication through over-the-counter ("otc") drug development programs, today announced results of an initial study to determine consumer comprehension of the messaging in its app technology ("app comp"), which has unique differences from the current drug facts label ("dfl"). of the 31 objectives, 29 scored >90% comprehension point estimate ("pe"), 30 scored >86.7% comprehension pe, and all scored > 80% comprehension pe.
PTPI Ratings Summary
PTPI Quant Ranking